NFATC3

Across TCGA pan-cancer cohorts, NFATC3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NFATC3 data layer compared with 20 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NFATC3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NFATC3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and OV are the cancer types where NFATC3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.985	0.464	<.001	37	view →
LUAD	OS	Quartile	II,III,IV	0.906	0.459	.020	10	view →
OV	DFS	Quartile	All	0.456	1.000	.047	8	view →
HNSC	OS	Median	III,IV	0.795	0.914	.027	8	view →
LSCC	OS	Median	All	0.886	0.730	.009	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NFATC3–PDAC (DFS)

Open the PDAC breakdown →